Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has released its unaudited financial results for the ...
The minister said five major pharma companies—Dr Reddy's Laboratories, Aurobindo Pharma, Hetero, Laurus Labs, and MSN Pharmaceuticals—have already committed to significant investments in the upcoming ...
RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...
Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...
Hyderabad-based Dr Reddy’s Laboratories (DRL) recorded a 9.5 per cent decline in its consolidated profit after tax (PAT), ...
Indian pharmaceutical major, Dr Reddy’s Laboratories share surged 3.1 per cent at Rs 1,312 a piece on the BSE in Wednesday’s intraday deals. This came after the pharma major on Tuesday recorded its ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment ...
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net ...
Dr Reddy's Labs reports 9.5 percent fall in consolidated net profit after tax to Rs 1342 crore in Q2
Indian generic drugmaker Dr Reddy's Laboratories recorded a 9.5 percent decline in its consolidated net profit after tax to ...
Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback